Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 17/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.52 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.49 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15066254 | 1.00 | F10 (0.61) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL16372458 | 0.82 | F10 (0.72) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7723895 | 0.81 | F10 (0.77) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL10272033 | 0.81 | F10 (0.77) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7723004 | 0.81 | F10 (0.77) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15110803 | 0.80 | F10 (0.59) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15110805 | 0.80 | F10 (0.59) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15618756 | 0.80 | MAOB (0.65) | F10 | |
| SCHEMBL12126891 | 0.80 | MAOB (0.65) | F10 | |
| SCHEMBL3207934 | 0.79 | GRM2 (0.50) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140378682-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING RIVAROXABAN | CADILA HEALTHCARE LIMITED (IN) | 2014-12-25 | — | — | US | claimed |
| WO-2013098833-A2 | PROCESSES AND INTERMEDIATES FOR PREPARING RIVAROXABAN | CADILA HEALTHCARE LIMITED (IN) | 2013-07-04 | — | — | WO | claimed |
| US-20140378682-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING RIVAROXABAN | CADILA HEALTHCARE LIMITED (IN) | 2014-12-25 | — | — | US | disclosed |
| WO-2013098833-A2 | PROCESSES AND INTERMEDIATES FOR PREPARING RIVAROXABAN | CADILA HEALTHCARE LIMITED (IN) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378682-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING RIVAROXABAN | VKORC1, VKORC1L1, F2 | F10 11/4885CYP1A2 16/4885CYP3A4 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.